Modular manufacturing: The key to unlocking mRNA expansion?
The evolving mRNA landscape has been marked by rapid advancements and a broadening scope of applications, primarily driven by the …
Post
-
-
Adapting to funding and operational hurdles in today’s clinical trials landscape
Against the backdrop of geopolitical tensions and economic measures such as tariffs, which are influencing supply chains across numerous industries, …
-
MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial
US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101 Phase II …
-
CTO East Coast 2025: Global oncology cell therapy market to hit $25bn by 2031
According to GlobalData analysis, currently marketed and pipeline cell therapy assets in oncology will generate sales of around $25bn by …
-
Rhythm’s stock climbs on encouraging Phase II obesity drug data
Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced body mass index …
-
CTO East Coast 2025: Global oncology cell therapy market to hit $25bn by 2031
According to GlobalData analysis, currently marketed and pipeline cell therapy assets in oncology will generate sales of around $25bn by …
-
Rhythm’s stock climbs on encouraging Phase II obesity drug data
Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced body mass index …
-
How to remain a top CDMO in ADC-led oncology
Contract development and manufacturing organisations (CDMOs) worldwide are facing a multitude of challenges, which are heightened considerably in oncology by …
-
Six challenges facing emerging biotechs and how to solve them
Handing over your molecule is a big step for emerging biotechs. The process of developing new drugs is complex and …
-
LEO Pharma reports results from interim analysis of Phase IIIb atopic dermatitis trial
LEO Pharma has reported positive outcomes from the 16-week interim analysis of the randomised Phase IIIb ADHAND trial of fully …
-
FDA approves Purespring’s application for Phase I/II trial of IgAN treatment
The US Food and Drug Administration (FDA) has approved Purespring Therapeutics’ investigational new drug (IND) application for PS-002, allowing the …
-
CTO East Coast 2025: AI can speed up all parts of clinical trial ecosystem
Artificial intelligence (AI) should soon be taking a greater role in areas including patient recruitment and in building efficiencies around …
-
Trump’s 200% tariff threat could send shockwaves through pharma supply chains
US President Donald Trump's 200% tariff threat on the pharmaceutical industry is a "shock" that will reverberate through global supply …
-
First subject dosed in Upstream Bio’s Phase II trial of verekitug for COPD
Upstream Bio has dosed the first subject in the randomised Phase II trial of verekitug, an antibody antagonist targeting the …
-
Enrolment concludes in Beacon Therapeutics’ trial of laru-zova for XLRP
Beacon Therapeutics has completed the enrolment in its randomised, registrational Phase II/III VISTA trial of laru-zova (laruparetigene zovaparvovec) as a …
